Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (Nasdaq: IMVT) will report financial results for the fourth quarter and fiscal year ended March 31, 2026 and provide a business update on Wednesday, May 20, 2026 at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) will report financial results for the fourth quarter and fiscal year ended March 31, 2026 and provide a business update on Wednesday, May 20, 2026 at 8:00 a.m. ET. Access details and the archived webcast will be available on Immunovant’s investor website.
Details
News Market Reaction – IMVT
On May 12, the first trading day after this news, IMVT closed 1.41% below the previous close.
Data tracked by StockTitan Argus for the May 12 session.
Key Figures
- Earnings call time
- 8:00 a.m. ET
- Scheduled earnings and business update on May 20, 2026
- Fiscal year-end
- March 31, 2026
- Fiscal year for upcoming reported results
- Earnings call date
- May 20, 2026
- Date of scheduled financial results and business update
Previous Earnings date Reports
-
Announcement of Q3 FY2025 earnings date and related business update call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.